

Case Study

CITELINE CONSULTING & ANALYTICS

Rare disease prioritization model and landscape analysis



Situation


A global pharmaceutical company required an objective assessment of multiple rare diseases to identify the most promising indications in which to develop preclinical candidate molecules.

Approach

Leveraging Citeline's proprietary datasets, our Consulting & Analytics team created a weighted prioritization model to assess each rare disease across multiple areas — including unmet need, market competition, development feasibility, and the client's target product profile — to produce the final ranking and recommendation. Further insight into the highest-ranked diseases was provided by a series of complementary disease landscapes.



Solution



Prioritization Model

Citeline created a weighted prioritization model to rank indications as the most attractive development opportunities for a set of preclinical assets.

Ranking Model

The client received an interactive Excel model, ranking multiple rare diseases as opportunities in which to pursue the development of its portfolio of preclinical candidates.



Parameters

Weightings could be set by the user for four broad parameter groups and over 30 specific sub-parameters.



Model Outputs



Model outputs were illustrated using dynamic bubble plots and heat mapping to facilitate the interpretation of final scores.



Impact

We developed a rigorous prioritization model and complemented it with in-depth disease analysis. The ranking not only highlighted the most promising indications for preclinical candidate molecules but also provided actionable recommendations to guide the client's strategic decision-making. Armed with insightful intelligence, the client could confidently allocate resources and prioritize initiatives that aligned with its overarching goals and objectives.

Example Deliverables



Value



Subject-matter expertise on a range of therapy areas to partner with you on your bespoke business needs




Leveraging market-leading products and real-world data (RWD) solutions



Validating, benchmarking, and refining data to assess feasibility




Accurate and credible recommendations you can trust for successful outcomes



Leverage the Citeline Consulting & Analytics team to assess the rare diseases landscape, using our deep domain expertise and access to extensive databases to compile a holistic view of the current landscape with state-of-the-art visualizations and insights.

[LEARN MORE](#)



Citeline, a [Norstella](#) company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.

Our global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world's most trusted life science partners, visit [Citeline.com](#)

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.